← board
CLNN
distress 9/10 · high distress / dilution risk$5.66-3%today-55% from 52w high
Lead: multiple sclerosis · est. market ~$25B (approx, global)
Revenue
pre-revenue
Liquidity
$6M
Runway
0.3 yrs
Shares 1y
+28%
Price & events
+4.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.7%
1D
-0.5%
1W
-1.9%
1M
-8.0%
3M
+6.6%
6M
+51.3%
1Y
+22.2%
2Y
-96.4%
5Y
-96.3%
All
Overview
- Market Cap
- $72.33M
- Enterprise Value
- $84.08M
- Volume
- 1.14K
- 52 Week Range
- $3.36 – $12.50
- Total Shares
- 12.78M
- Float Shares
- 10.50M
- Short %
- 10.35%
- % Held by Insiders
- 17.06%
- % Held by Institutions
- 20.44%
- RVOL
- 0.02x
- Beta
- 0.92
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 6
- first quarter of 2027Guided 70%trial initiationsecondaryPhase 3CNM-Au8 · Plan to commence Phase 3 confirmatory studySEC 8-K
- third quarter of 2026Guided 70%regulatory submissionFiled (NDA/BLA)CNM-Au8 · Plan to submit NDA under accelerated approval pathwaySEC 8-K
- 2026-05-04fda agreementCNM-Au8 · FDA agreed that NfL could serve as surrogate endpoint for accelerated approvalSEC 8-K
- April 8, 2025conferencedata presentationsecondaryPhase 2CNM-Au8 · Presented evidence of remyelination and neuronal repair in VISIONARY-MS LTE at AAN Late-Breaking Science Session.SEC 8-K
- 2024-12-10fda agreementCNM-Au8 · FDA provided a potential path for accelerated approval through submission of additional CNM-Au8 biomarker data in ALS.SEC 8-K
- October 23, 2024conferencedata presentationsecondaryPhase 3CNM-Au8 · Preliminary design for RESTORE-ALS Phase 3 trial presented at 2024 NEALS Meeting.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-04D. Boral CapitalBuy
- 2026-05-04HC Wainwright & Co.Buy
- 2026-03-13Canaccord GenuityBuy
- 2026-03-12D. Boral CapitalBuy
- 2026-01-09D. Boral CapitalBuy
- 2025-12-10D. Boral CapitalBuy
Competitors — multiple sclerosis
- NVSEFNOVARTIS AG$292.0B · D3
- NVSNOVARTIS AG$291.7B · D1
- SNYSanofi$52.5B · D1
- BIIBBIOGEN INC.$29.2B · D2
- TGTXTG THERAPEUTICS, INC.$8.1B · D0
- ZBIOZenas BioPharma, Inc.$2.0B · D3
- AUTLAutolus Therapeutics plc$378M · D8
- CTNMContineum Therapeutics, Inc.$334M · D2
- IMUXIMMUNIC, INC.$202M · D2
- TLSATiziana Life Sciences Ltd$114M · D6
Recent news
- 2026-07-21When Will Clene Inc. (NASDAQ:CLNN) Breakeven? - simplywall.st
- 2026-07-21When Will Clene Inc. (NASDAQ:CLNN) Breakeven? - Sahm
- 2026-07-18Clene (CLNN) Proxy filing Summary - Quartr
- 2026-07-15Clene (CLNN) Q1 2026 earnings summary - Quartr
- 2026-07-15Enterprise value to EBIT forward of Clene Inc. – NASDAQ:CLNN - TradingView
- 2026-07-13Enterprise value to revenue forward of Clene Inc – FWB:84C0 - TradingView
- 2026-07-12Clene Inc. (CLNN) Edges Higher, Testing Key Resistance at $6.58 - Bollinger Expansion - dars.gov.et
- 2026-07-10Clene (CLNN) Q2 Virtual Investor Summit Event earnings summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.